Overview

Efficacy and Safety of Stannsoporfin in Neonates

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, sham injection-controlled (placebo) masked trial of a single intramuscular injection of Stannsoporfin compared to "sham" (placebo) in healthy term and near-term newborns admitted to the well-baby nursery and enrolled with "intention to treat".
Phase:
Phase 3
Details
Lead Sponsor:
InfaCare Pharmaceuticals Corporation
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Treatments:
Tin mesoporphyrin